Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma
- 1Department of Allergy, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China
Abstract
Background/Objectives: Asthma is a heterogeneous chronic inflammatory airway disease. In China, achieving rapid asthma control remains a major challenge, and a substantial proportion of patients remain inadequately controlled despite regular use of standard inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated clinical efficacy in trials, but its real-world effectiveness and safety in China remain insufficiently characterized. This study evaluated FF/UMEC/VI (100/62.5/25 μg) in Chinese patients with uncontrolled asthma. Methods: This retrospective study included patients with asthma treated with FF/UMEC/VI at the Department of Allergy, Peking Union Medical College Hospital, between July 2021 and March 2024. The cohort included patients with no prior inhaled medication, irregular prior inhaled therapy, or regular prior inhaled therapy with inadequate control, reflecting a real-world spectrum of patients requiring treatment intensification. Assessments were performed at baseline and 1, 3, and 6 months after treatment initiation. The primary endpoint was the change in forced expiratory volume in 1 s (FEV1) at 1 month. Secondary outcomes included changes in FEV1, percent predicted FEV1, and FEV1/forced vital capacity (FEV1/FVC), and safety. Results: Thirty patients were analyzed. FEV1 increased significantly at 1 month and remained above baseline at 3 and 6 months. Percent predicted FEV1 and FEV1/FVC also improved significantly at all follow-up visits. Maintenance therapy was reduced in 53.3% of patients. No serious adverse events occurred; reported events were mainly local throat discomfort and increased sputum production. Conclusions: In real-world practice, FF/UMEC/VI was associated with improved lung function measures in Chinese patients, including previously untreated, irregularly treated, and regularly treated but uncontrolled patients, with an acceptable safety profile. Larger prospective studies are warranted to confirm its long-term effectiveness and identify appropriate patient populations in China.
Related
- The Association of COPD Patients' and Caregivers' KAP with Inhaler Adherence: An Actor-Partner Interdependence Model Analysis.
- Topical Fluticasone Propionate Versus Fusidic Acid for Zoon’s Balanitis in Men: A Prospective, Open-Label, Non-Randomised Comparative Study with an Exploratory Long-Term Assessment
- Digital inhaler data in routine asthma care: defining a minimal dataset for clinical decision support (AURORA): a modified delphi study
- COPD: real-world evidence on single-inhaler triple therapy and the emergence of biologic therapy
- Deciphering the Benefits and Risks of Single-Inhaler Triple Therapy in COPD.
BibTeX
@article{li2026realworld,
title = {{Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma}},
author = {Anqi Li and Zhouxian Pan and Juan Liu and Lun Li and Xin Li and Zhirong Du and Jia Yin},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207990},
url = {https://www.mdpi.com/2077-0383/15/20/7990},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma
AU - Anqi Li
AU - Zhouxian Pan
AU - Juan Liu
AU - Lun Li
AU - Xin Li
AU - Zhirong Du
AU - Jia Yin
PY - 2026
DA - 2026/10/15
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207990
UR - https://www.mdpi.com/2077-0383/15/20/7990
AB - Background/Objectives: Asthma is a heterogeneous chronic inflammatory airway disease. In China, achieving rapid asthma control remains a major challenge, and a substantial proportion of patients remain inadequately controlled despite regular use of standard inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated clinical efficacy in trials, but its real-world effectiveness and safety in China remain insufficiently characterized. This study evaluated FF/UMEC/VI (100/62.5/25 μg) in Chinese patients with uncontrolled asthma. Methods: This retrospective study included patients with asthma treated with FF/UMEC/VI at the Department of Allergy, Peking Union Medical College Hospital, between July 2021 and March 2024. The cohort included patients with no prior inhaled medication, irregular prior inhaled therapy, or regular prior inhaled therapy with inadequate control, reflecting a real-world spectrum of patients requiring treatment intensification. Assessments were performed at baseline and 1, 3, and 6 months after treatment initiation. The primary endpoint was the change in forced expiratory volume in 1 s (FEV1) at 1 month. Secondary outcomes included changes in FEV1, percent predicted FEV1, and FEV1/forced vital capacity (FEV1/FVC), and safety. Results: Thirty patients were analyzed. FEV1 increased significantly at 1 month and remained above baseline at 3 and 6 months. Percent predicted FEV1 and FEV1/FVC also improved significantly at all follow-up visits. Maintenance therapy was reduced in 53.3% of patients. No serious adverse events occurred; reported events were mainly local throat discomfort and increased sputum production. Conclusions: In real-world practice, FF/UMEC/VI was associated with improved lung function measures in Chinese patients, including previously untreated, irregularly treated, and regularly treated but uncontrolled patients, with an acceptable safety profile. Larger prospective studies are warranted to confirm its long-term effectiveness and identify appropriate patient populations in China.
SN - 2077-0383
ER -